866-997-4948(US-Canada Toll Free)

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 50 Pages

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2017

Summary

According to the recently published report 'Protein Phosphatase 2A - Pipeline Review, H2 2017'; Protein Phosphatase 2A (PP2A or EC 3.1.3.16) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes.

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Protein Phosphatase 2A (PP2A) is an enzyme encoded by the PPP2CA gene. PP2A plays important roles in regulation of cell cycle, signal transduction, cell differentiation, and transformation. Its activity is related to several diseases, including neurodegenerative diseases and cancer.

The report 'Protein Phosphatase 2A - Pipeline Review, H2 2017' outlays comprehensive information on the Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Gastrointestinal, Ophthalmology and Respiratory which include indications Alzheimer's Disease, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer, Allergic Conjunctivitis, Asthma, Brain Ischemia, Breast Cancer, Breast Tumor, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Crohn's Disease (Regional Enteritis), Depression, Idiopathic Pulmonary Fibrosis, Melanoma, Myelodysplastic Syndrome, Myocardial Ischemia, Neuroblastoma, Pancreatic Cancer, Parkinson's Disease, Pheochromocytoma, Renal Cell Carcinoma, Sarcomas, Septic Shock, Solid Tumor, Ulcerative Colitis, Uveal Melanoma and Uveitis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Protein Phosphatase 2A (PP2A or EC 3.1.3.16)
- The report reviews Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics and enlists all their major and minor projects
- The report assesses Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Protein Phosphatase 2A (PP2A or EC 3.1.3.16)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Protein Phosphatase 2A (PP2A or EC 3.1.3.16) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Overview 6
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 12
Products under Development by Universities/Institutes 15
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Therapeutics Assessment 17
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Companies Involved in Therapeutics Development 23
Ampio Pharmaceuticals Inc 23
Cyano Biotech GmbH 23
Lixte Biotechnology Holdings Inc 23
PEP-Therapy SAS 24
Re-Pharm Ltd 25
Signum Biosciences Inc 25
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Drug Profiles 27
Drugs to Activate PP2A for Oncology - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
LB-100 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
NCE-001 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
PEP-010 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
RP-0217 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Small Molecule to Activate PP2A for Lung Cancer - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecule to Activate PP2A for Parkinson Disease and Alzheimer's Disease - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Small Molecule to Inhibit PPP2R2A for Oncology - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Small Molecules to Inhibit PP1 and PP2A for Oncology - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
TD-X - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
VEL-015 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Dormant Products 41
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Product Development Milestones 42
Featured News & Press Releases 42
Jun 13, 2017: Re-Pharm and Cresset Discovery Services to attend BIO International for partnering 42
Apr 17, 2017: Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, LB-100, Reported to be a Potentiator of Immunotherapy in an Animal Model 42
Mar 09, 2017: Late-Breaking Abstract on LB-100, Lixte Biotechnologys Protein Phosphatase 2A Inhibitor, in Combination with a PD-1 Inhibitor in an Animal Model to be Presented at the AACR Annual Meeting 42
Jan 04, 2017: First-In-Human Assessment of LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, Published in Clinical Cancer Research 43
Nov 03, 2016: Re-Pharm to present at IDDST, Nanjing, China and available for one-to-one meetings 43
Mar 24, 2016: Re-Pharm compound with steroid-sparing properties granted second patent for ophthalmic indications 44
Feb 03, 2016: Lixte Biotechnology Holdings Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression 44
Nov 24, 2015: Re-Pharm awarded patent for repurposed compound for treatment of inflammatory disorders 45
Nov 06, 2015: Lixte Biotechnology Holdings Announces That Its Novel Protein Phosphatase 2A Inhibitor Is Associated With Stabilization Of Several Types Of Cancer Without Dose-Limiting Toxicity 45
Sep 17, 2015: Lixte Biotechnology Holdings Engages BioPharmaWorks To Enhance Development Of Its Pipeline Of Novel Compounds 46
Feb 25, 2015: Lixte Biotechnology's Lead Compound Reported To Be Active Against Hematologic Cancers In Pre-Clinical Studies 46
Feb 10, 2015: Re-Pharm identifies novel anti-inflammatory activity for existing compound 47
Jan 23, 2015: Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 47
Nov 06, 2014: Lixte's LB-100 Selected as One of Informa and Kantar Health's 2014 Top 10 Most Interesting Oncology Projects to Watch 47
Jun 18, 2014: Lixte's Lead Compound LB-100 Reported To Enhance Chemotherapy Effectiveness In Animal Models Of Liver Cancer 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 49
Disclaimer 50

List of Tables
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Indications, H2 2017 9
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 11
Number of Products under Development by Companies, H2 2017 12
Products under Development by Companies, H2 2017 13
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14
Number of Products under Investigation by Universities/Institutes, H2 2017 15
Products under Investigation by Universities/Institutes, H2 2017 16
Number of Products by Stage and Mechanism of Actions, H2 2017 18
Number of Products by Stage and Route of Administration, H2 2017 20
Number of Products by Stage and Molecule Type, H2 2017 22
Pipeline by Ampio Pharmaceuticals Inc, H2 2017 23
Pipeline by Cyano Biotech GmbH, H2 2017 23
Pipeline by Lixte Biotechnology Holdings Inc, H2 2017 24
Pipeline by PEP-Therapy SAS, H2 2017 25
Pipeline by Re-Pharm Ltd, H2 2017 25
Pipeline by Signum Biosciences Inc, H2 2017 26
Dormant Projects, H2 2017 41

List of Figures
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Top 10 Indications, H2 2017 9
Number of Products by Mechanism of Actions, H2 2017 17
Number of Products by Stage and Mechanism of Actions, H2 2017 17
Number of Products by Routes of Administration, H2 2017 19
Number of Products by Stage and Routes of Administration, H2 2017 19
Number of Products by Molecule Types, H2 2017 21
Number of Products by Stage and Molecule Types, H2 2017 21

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *